iMDx to Showcase GraftAssure in Kidney Health Forum with Key Opinion Leader
Event summary
- iMDx will participate in the U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026, featuring a KOL discussion and investor meetings.
- The KOL discussion will include iMDx CEO Josh Riggs and Prof. Dr. Med. Klemens Budde, a leading kidney transplantation researcher.
- Dr. Budde will provide clinical insights into the use of iMDx’s GraftAssure dd-cfDNA technology in kidney transplant care.
- The discussion will explore the potential of GraftAssure in assessing treatment response and tailoring anti-rejection therapy.
The big picture
iMDx’s participation in the U.S. Bancorp I BTIG Kidney Health Forum underscores the growing importance of molecular diagnostics in transplant care. The collaboration with Prof. Dr. Med. Klemens Budde, a renowned expert in kidney transplantation, highlights the strategic value of clinical validation in driving technology adoption. As the market for personalized medicine expands, iMDx’s focus on blood-based testing could position it as a key player in the diagnostics space.
What we're watching
- Technology Adoption
- How the clinical validation of GraftAssure will influence its adoption in kidney transplant care.
- Regulatory Pathway
- The pace at which iMDx can secure regulatory approvals for GraftAssure and other diagnostic products.
- Market Positioning
- Whether iMDx can differentiate itself in the competitive landscape of molecular diagnostics.
Related topics